// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Complement C5a Receptor Inhibitor Avacopan Improves Renal Function in ANCA Vasculitis

Jayne DavidR.W - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Anti-neutrophil cytoplasmic antibody-associated vasculitis

Cyclophosphamide

Prognostic Value of Persistent Proteinuria and Hematuria After Induction Therapy in ANCA-Associated Vasculitides

Benichou Nicolas - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

End stage renal disease

N/A

Belimumab (BEL) Improves Renal Outcomes in Active Lupus Nephritis (LN): A Phase 3 Randomized, Placebo (PBO)-Controlled Trial

Rovin BradH - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Microvascular complications of diabetes 1

Mycophenolate mofetil

24-Week Interim Analysis of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Atacicept in Patients with IgA Nephropathy and Persistent Proteinuria

Barratt Jonathan - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

IgA nephropathy

N/A

LNP023: A Novel Oral Complement Alternative Pathway Factor B Inhibitor Safely and Effectively Reduces Proteinuria in C3 Glomerulopathy

Wong EdwinKwan Soon - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

C3 glomerulopathy

N/A

Characteristics and Outcomes of Pregnancy-Triggered Atypical Hemolytic-Uremic Syndrome (aHUS): Global aHUS Registry Analysis

Fakhouri Fadi - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Atypical hemolytic uremic syndrome

N/A

Does Screening for Coronary Artery Disease Predict Cardiac Outcomes Following Renal Transplantation?

Nimmo Ailish - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

N/A

Design of the CALCIPHYX Study, a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of SNF472 for Treating Calciphylaxis

Sinha Smeeta - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Calciphylaxis

Inositol

International Registry of COVID-19 Infection in GN (IRoc-GN): Impact of COVID-19 in Patients with Glomerular Disease

Waldman MerylA - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Glomerulonephritis

N/A

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atrasentan in Patients with IgA Nephropathy (The ALIGN Study)

L Heerspink HiddoJan - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Primary glomerulonephritis

atrasentan

AKI Identification: Use of Electronic AKI Alerts vs. Electronic Health Records in Hospital Episode Statistics

Savino Manuela - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Region-wide Implementation of Best Practice in AKI

Rao Anirudh - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

One-Year AKI Stage 3 Outcome in Elderly Patients at a Secondary Care Hospital in the United Kingdom

Rathod JeetendraRamesh - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Using a Peritoneal Dialysis Catheter as a Tool for AKI Prevention in a Patient with Refractory Cardiac Ascites: A Case Report

Rashid RajaMuhammad - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Modelling the Clinical and Economic Burden of Anaemia in Patients with CKD

Darlington OliverT - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Anemia

N/A

Clinical Outcomes in Patients with Anemia in CKD Using Linked US Claims and Electronic Health Records

Wittbrodt EricT - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Anemia

N/A

Predicting the Optimal Approach to IV Iron: Understanding the Requirements to Attain and Maintain Target Haemoglobin in Non-Haemodialysis CKD

Brown Christopher - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Iron isomaltoside

Treatment Pathways of Non-Dialysis-Dependent CKD Patients with Anemia: A Report from the DISCOVER CKD Retrospective Cohort

Wittbrodt EricT - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Non-dialysis-dependent chronic kidney disease

N/A

Physician Attitudes Toward Diagnosis, Treatment Initiation, and Unmet Needs in the Management of Anemia due to CKD: Results from a Real-World Survey in Germany, Italy, and the United Kingdom

Kabra Madhusudan - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Anemia

N/A

Patient Preferences Study for Treatments of Anemia in CKD Patients Not on Dialysis (NDD)

Alexandre Ana filipa - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Anemia

N/A

Copyright © 2026. QuantiNova All rights reserved